Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy

Autor:	Jeong Yeal Ahn, Sanghui Park, Hyung Sun Kim, Sun Jin Sym, Jae Hoon Lee, Dong Bok Shin, Min Young Rim, Jinny Park, Minkyu Jung, Junshik Hong, Eun Kyung Cho, Kyung-Hee Kim
Rok vydání:	2011
Předmět:	Oncology Adult Male Cancer Research medicine.medical_specialty Pathology Vincristine Cyclophosphamide Prednisolone Antibodies Monoclonal Murine-Derived Young Adult International Prognostic Index immune system diseases Antigens Neoplasm hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Doxorubicin Aged Aged 80 and over business.industry Hematology Middle Aged medicine.disease Prognosis Immunohistochemistry Survival Analysis Lymphoma Treatment Outcome Rituximab Female Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma medicine.drug
Zdroj:	Leukemialymphoma. 52(10)
ISSN:	1029-2403
Popis:	The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were evaluated with respect to clinical characteristics, treatment efficacy, and survival. Immunohistochemistry of bcl-2, CD10, bcl-6, and MUM-1 was performed and patients were sub-classified as germinal center B-cell-like (GCB) or non-GCB type according to the Hans algorithm. There was no significant difference in overall survival (OS) between patients with GCB and those with non-GCB. Although there was no significant difference in OS between high-intermediate and high risk groups as classified by the standard International Prognostic Index (IPI; p = 0.50), all three groups with the revised IPI had a clear-cut separation for event-free survival and OS. The revised IPI better predicted survival than did the standard IPI in patients with DLBCL treated with R-CHOP. The Hans classification had no prognostic value.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::236894b4f07e498f4763b120e29220d3 https://pubmed.ncbi.nlm.nih.gov/21718130 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.